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Contaminated food is the usual source of human 
campylobacter infection (predominantly Campylo-  
bacter jejuni and C. coli) [1,2], and the presence of 
fluoroquinolone-resistant strains in the food chain has 
raised concerns that the human disease, which responds 
to oral quinolones such as ciprofloxacin, will be com- 
promised. However, because of the low mortality and 
self-limiting nature of campylobacter enteritis, many 
would consider quinolone therapy to be unjustified 
unless the patient is immunocompromised or the 
infection is extraintestinal. The majority of infections 
are sporadic and, although not usually associated with 
outbreaks, there is a strong association with preparing 
and/or eating poultry [3-51. Outbreaks of campylo- 
bacter enteritis have been associated with contaminated 
water and raw milk [2,3]. Fluoroquinolones have good 
activity against C. jejuni  and C. coli with MIC90s 
generally of 0.25 mg/L [6-8]. Campylobacter strains with 
inherent resistance to nalidixic acid are less susceptible 
to fluoroquinolones, with a higher MIC90 of 1 mg/L. 
Fluoroquinolones concentrate within the intestinal 
mucosa and feces to high levels [9]. Clinical trials with 
fluoroquinolones have demonstrated a good response, 
and it was further suggested, and reiterated recently, 
that fluoroquinolones would be useful for the pro- 
phylaxis of travelers’ diarrhea, as thase agents gave 
symptomatic relief and shortened the duration of dness 
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[lo]. However, there is clear evidence that microbio- 
logical eradication is no quicker in the presence of 
fluoroquinolone therapy [I 11. Resistance of Campylo- 
bacter strains to fluoroquinolone antimicrobials has 
been recognized for several years, and emergence of 
resistance after fluoroquinolone therapy in humans has 
also been reported [12]. The MIC of ciprofloxacin for 
these bacteria ranges from 32 to 256 mg/L. Quinolone- 
resistant Campylobactev strains are being isolated with 
increasing frequency in several European countries 
[12]. 
EPIDEMIOLOGY OF RESISTANCE TO FLUOROQUINOLONES 
The number of Campylobacter strains resistant to the 
recommended breakpoint concentration of fluoro- 
quinolones (1-4 mg/L depending on the agent and 
country) differs between countries, and also within 
countries. Reasons for this include the association with 
travel, the fact that some countries/laboratories do not 
test Campylobacter strains for susceptibility to fluoro- 
quinolones, and the veterinary use of quinolones in 
animals. In 1990, Endtz et al [13] observed that 11% 
of human isolates of Campylobacter isolated in The 
Netherlands were resistant to nalidixic acid or cipro- 
floxacin; by 1991, these authors reported that 30-35% 
of isolates were resistant. Currently, the reported 
frequencies of resistance in Spain range from 29% to 
82% (Palma de Mallorca [14], Madrid [15], Orense 
[16,17], San Sebastian [18]). In the UK, there has been 
a steady increase in the numbers of fluoroquinolone- 
resistant Campylobacter strains isolated since 1991 [4]. In 
1992, Sjogren et al [19] suggested that there had been 
a small increase in the number of resistant Campylobacter 
strains over the previous decade and that most cases had 
been acquired outside Sweden. In Canada, Harnett et 
al [20], reported that the percentages of Campylobacter 
isolates resistant to fluoroquinolones were 17%, 10.4% 
and 14.5% for 1992, 1993 and 1994, respectively; 
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however, there was no information about the country 
of origin of retail poultry or use of fluoroquinolones. 
In Thailand [21], it has been suggested that at least 50% 
of isolates are fluoroquinolone resistant. For the USA, 
recent data from Minnesota suggest that there was also 
an increase in the numbers of fluoroquinolone-resistant 
Campylobacter strains isolated in 1997 compared with 
1996 [22]. 
FAILURE OF FLUOROQUINOLONE THERAPY FOR 
CAMPYLOBACTER INFECTIONS 
Fluoroquinolone-resistant Campylobacter strains arising 
after treatment for enteritis were first observed in the 
late 1980s, and several international reports document 
up to 20% of patients relapsing because of the emer- 
gence of a resistant isolate only inhibited by 32 mg/L 
ciprofloxacin or more [ 1 1,23-281. Failure of cipro- 
floxacin therapy of campylobacter infection in an AIDS 
patient has been reported [28,29]. However, failure of 
ciprofloxacin therapy does not account for the numbers 
of ciprofloxacin-resistant strains isolated in microbiol- 
ogy laboratories, and it is clear that many patients have 
not received any treatment for their illness before 
presenting to their general practitioner (GP) and there- 
fore it must be presumed that the strain was already 
fluoroquinolone resistant prior to causing an infection. 
It has been difficult to obtain published data des- 
cribing evidence of failure of fluoroquinolones to treat 
an enteritis with a fluoroquinolone-resistant Campylo- 
bacter strain. However, as this infection is usually 
considered to be self-limiting, it is not known how 
many patients have been treated. Gaunt (personal 
communication) performed a small retrospective study 
in 1998, whereby a questionnaire was sent to the GPs 
of 39 patients who had had a fluoroquinolone-resistant 
campylobacter enteritis in 1997; prior to isolation of 
the resistant strain, one of 39 had received ciprofloxacin 
10 days previously to treat a ciprofloxacin-susceptible 
campylobacter infection and one of 39 had self- 
medicated with norfloxacin purchased in Thailand. A 
further seven patients received ciprofloxacin after a 
stool specimen was sent to the laboratory; of these, one 
patient was a clear microbiological failure 10 days after 
treatment. 
MECHANISM OF FLUOROQUINOLONE RESISTANCE 
In Gram-negative bacteria, DNA gyrase (type I1 
topoisomerase) and DNA topoisomerase IV are the 
primary and secondary targets of fluoroquinolone 
antibiotics, respectively [30]. Mutations in the genes 
g y r A  and/or parC that encode the A subunits of these 
two enzymes are the most common mechanisms 
observed in clinical isolates of Gram-negative bacteria 
[31]. Segreti et al [32] purified DNA gyrase from a 
ciprofloxacin-resistant C. jejuni strain and found that 
the enzyme was 8-16-fold less sensitive to inhibition by 
ciprofloxacin than the enzyme isolated from the paired 
ciprofloxacin-susceptible pre-therapy isolate. In addi- 
tion, both this resistant isolate and that from the second 
patient who failed therapy accumulated lower concen- 
trations of ciprofloxacin than the pre-therapy isolates. 
In strains requiring 16-64 mg/L ciprofloxacin for in- 
hibition, Wang et al identified mutations in g y r A  at 
position 86 (threonine), which is analogous to the site 
in g y r A  in other bacteria shown to give rise to 
fluoroquinolone resistance [33]. In 1995, Everett et al 
[34] found the same mutations in human and chicken 
isolates from the UK, as have Ruiz et a1 [35]. However, 
mutations in gyrA and MIC values do not correlate, 
suggesting that other factors are contributing to the 
overall resistance phenotype. Recently, p a r C  of C. jejuni 
[36] has been described, and a mutation at arginine 139 
found in resistant isolates. 
CROSS-RESISTANCE TO NON-QUINOLONE AGENTS 
As a consequence of the high numbers of fluoro- 
quinolone-resistant Campylobacter strains isolated from 
humans in some countries, it has been proposed that, 
where antimicrobial chemotherapy is required, the 
drug of choice should remain erythromycin. However, 
there have been varying reports of resistance to 
erythromycin among Carnpylobacter strains, sometimes 
combined with resistance to fluoroquinolones [37-391. 
Rautelin et a1 [40] found that five of 30 (17%) 
consecutive ciprofloxacin-resistant isolates were also 
erythromycin resistant, but that of 30 erythromycin- 
resistant isolates none were ciprofloxacin resistant, 
suggesting that erythromycin-resistant isolates are 
becoming ciprofloxacin resistant. 
There has been one study of paired isolates where 
the post-therapy ciprofloxacin-resistant isolate had co- 
incidentally become resistant to both erythromycin and 
tetracycline [28]. In contrast, in other studies no cross- 
resistance between fluoroquinolones and erythromycin 
has been observed [4,19,41,42]. A multidrug efflux 
pump has been described for C. jejuni [43], with 
overexpression producing strains only susceptible to 
16 mg/L of ciprofloxacin and cefotaxime, and 4 mg/L 
(decreased susceptibility) of chloramphenicol, tetra- 
cycline and erythromycin. 
Transferable resistance to tetracycline and/or kana- 
mycin has been detected in fluoroquinolone-resistant 
Carnyylobarter strains [18]. Gaunt and Piddock [4] also 
observed cross-resistance to tetracycline; this may be 
attributable to transferable resistance in addition to the 
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fluoroquinolone resistance. However, no cross-resis- 
tance was seen with erythromycin. Taylor et al [8] have 
shown that most Campylobacter strains are resistant to 
novobiocin (MIC 32-512 mg/L). 
RISK FACTORS ASSOCIATED WITH ACQUIRING 
STRAINS 
FLUOROQUINOLONE-RESISTANT cmwvumcrER 
For residents of the UK, there is an association between 
acquisition of ciprofloxacin-resistant Campylobacter 
strains and recent travel overseas. Gaunt and Piddock 
[4] found, in a case-control study of 15 cases (compared 
with a control group of 24 cases with ciprofloxacin- 
susceptible campylobacter enteritis), that there was a 
statistically significant association between the acquisi- 
tion of ciprofloxacin-resistant isolates and travel outside 
the UK in the 3 months preceding infection. Of the 
total number of cases (109), 39% were associated with 
foreign travel, the remainder (61%) having acquired 
their infection within the UK. As a follow-up, in the 
recent GP questionnaire (see above), 18 of 39 patients 
had a history of overseas travel, predominantly to the 
Iberian peninsula and Thailand, as was previously found 
(P.N. Gaunt, personal communication). 
VETERINARY USE OF QUINOLONES AND SELECTION 
STRAINS 
OF FLUOROQUINOLONE-RESISTANT c m w u m c m  
The predominant reservoir of C. jejuni and C. coli is 
thought to be poultry [2] (although Campylobacter 
strains have been isolated from other foods, including 
pork), and campylobacters are recognized food-borne 
pathogens. In The Netherlands, flumequine has been 
used in veterinary medicine since the early 1980s; in 
1987, the veterinary fluoroquinolone enrofloxacin was 
introduced, and in 1988 ciprofloxacin was licensed for 
human use [44]. By 1993, 29% ofveterinary isolates of 
Campylobacter were resistant to nalidixic acid, flum- 
equine, enrofloxacin and ciprofloxacin, and it was 
proposed by Endtz et al [44] that extensive use of 
quinolones in veterinary medicine in The Netherlands 
for meat, poultry and milk production contributed 
to the high frequency of fluoroquinolone-resistant 
Canipylobacter strains isolated from humans, since in 
1982 no resistant strains had been isolated. 
Jacobs-Reitsma et al [45] have shown in an 
experimental study that, at slaughter, all Campylobacter- 
colonized broilers exposed to enrofloxacin harbored 
fluoroquinolone-resistant Cumpylobacter strains. There 
are no published data on the prevalence of fluoro- 
quinolone-resistant Campylobacter strains in animals, 
including poultry known to have been exposed to 
fluoroquinolones. However, in animals known not to 
be exposed to fluoroquinolones, the data suggest that 
fluoroquinolone resistance is rare [46-481. 
ISOLATION OF CIPROFLOXACIN-RESISTANT 
c A M P Y u m c m  STRAINS FROM FOOD 
Despite the use of enrofloxacin in mainland Europe, 
there was no license for this agent for veterinary use in 
the UK until November 1993, and little was used 
before January 1994. Therefore, the UK could be 
considered a good ‘control’ to determine the effect of 
the veterinary use of fluoroquinolones upon the 
emergence of fluoroquinolone-resistant food-borne 
pathogens. However, much of the poultry is imported 
from Europe, and so a hstinction is required between 
UK-bred birds and those from elsewhere. In a small 
study by Gaunt and Piddock [4], Campylobacter strains 
were isolated from 37 of 64 (57.8%) UK-bred birds, 
with only one strain being ciprofloxacin resistant. In 
contrast, Campylobacter strains were isolated from 26 of 
50 (52%) non-UK chickens, and seven (27%) were 
ciprofloxacin resistant. A small follow-up study in 1997 
demonstrated a similar difference: two of 36 (6%) 
ciprofloxacin-resistant Campylobacter strains were iso- 
lated from UK-bred chicken, compared with 23 of 41 
(56%) for non-UK-bred chicken (Gaunt, personal 
communication). While the two studies are not directly 
comparable, because of minor differences in method- 
ology, resistance does not yet appear to have emerged 
in UK poultry following the licensing of enrofloxacin. 
Indeed, resistance among imported produce is patchy. 
In the 1997 study, 100 chicken portions were purchased 
from eight retail outlets: 50 portions from 12 producers 
in the UK, and 50 portions from five producers in other 
European countries (Denmark, France and The 
Netherlands). Resistant strains were found for only two 
of the 12 UK producers and for only three of the five 
non-UK producers. 
Geilhausen et a1 [49] examined 61 9 Campylobucter 
isolates from chicken meat produced in Germany, 
France and The Netherlands, and found that 22 (3.6%) 
were fluoroquinolone resistant (although the concen- 
tration used to determine resistance was not stated). 
However, pockets of resistance were noted, with four 
of 10 isolates from one meat batch being resistant to 
enrofloxacin. 
ARE CAMP YLOBACTFR STRAINS ISOLATED FROM 
ANIMALS THE SAME TYPE AS THOSE ISOLATED 
FROM HUMANS? 
There appears to be some dispute as to whether the 
same types of Campylobucter are isolated from animals 
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and humans; however, there are few published studies, 
and typing of Campylobacter is still at  an early stage, with 
adoption of a universal method not yet achieved. It 
appears that a combination of Penner serotyping and 
pulsed-field gel electrophoresis (PFGE) will be used by 
reference laboratories (J.E. Moore, personal com- 
munication). The relationship between PFGE type and 
antibiotic susceptibility, if any, has yet to be determined. 
Molecular typing (digestion of chromosomal DNA by 
restriction endonucleases, and subsequent Southern 
blotting) of Campylobacter strains from poultry and 
humans gave rise to two polymorphisms: 78% of the 
isolates fiom chickens and 29% of the human isolates 
gave rise to pattern 1; 22% of the isolates from chickens 
and 71% of the human isolates gave rise to pattern 2 
[50]. These data suggest that although the proportions 
of the isolate types differ between poultry and humans, 
by ths method there was similarity between isolates of 
chicken and human origin. In a small study with PFGE 
to type Cumpylobacter strains, Gielhausen and Mauff 
[51] found that a few isolates from chickens and humans 
were identical, but the majority of strains had different 
profiles. 
CONSEQUENCES OF INFECTION BY FLUOROQUINOLONE- 
RESISTANT CAMP YLOBACTER STRAINS 
Laboratories can no longer rely upon susceptibility to 
nalidixic acid as a method for distinguishing between 
the different Campylobacter species, as those previously 
thought to be susceptible, such as C. jejtrni, are increas- 
ingly fluoroquinolone resistant. For those individuals 
with a complicated campylobacter infection caused by 
a fluoroquinolone-resistant strain, it is unlikely that a 
fluoroquinolone will eradicate the infection. There is 
some evidence of failure of fluoroquinolone therapy for 
fluoroquinolone-resistant campylobacter enteritis, but 
as not all patients with this infection will receive 
antimicrobial chemotherapy, it is unclear how many 
patients have or will be adversely affected. If the treat- 
ment of campylobacter infection is essential, suscept- 
ibility to the fluoroquinolone of choice should be 
determined and treatment modified if fluoroquinolone 
resistance is detected. 
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